Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

Wyeth

Status and phase: Completed; Phase 2

Conditions: Schizophrenia

Treatments: Drug: SCA-136 (400 mg); Drug: SCA-136 (200 mg); Drug: placebo; Drug: olanzapine (15 mg)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00265551

3153A1-202

Details and patient eligibility

About

The purpose of this study is to determine whether a low dose and a high dose of the study drug SCA-136 are effective and safe in the treatment of schizophrenia requiring hospitalization.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of schizophrenia
• Ability to remain hospitalized for at least first 4 weeks of study
• Needs hospitalization due to worsening of schizophrenia

Exclusion criteria

• Type 1 or 2 diabetes
• Previous use of clozapine
• Serious medical illness other than schizophrenia

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind